/TRDA

Entrada Therapeutics Inc

TRDA

$6.80USD↑+5.92%+0.38 today

MARKET CAP

264.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $7

52W RANGE

$5

$16

AI Summary

Stalk

StalkMedium

Price has formed a bullish pivot point above the 9EMA and 20EMA through the flattening 50 SMA, signaling structural repair and medium-term mean reversion opportunity within an overall downtrend. However, short-term extension and RSI near overbought levels suggest waiting for a clean pullback into the rising EMAs near the recent support zone before committing. Patience for a retracement into the $7.00–$7.20 area aligns with the COMP strategy’s emphasis on confirmation and controlled engagement.

↑Current $7.26 vs. $17.50 average analyst target (~140% upside)
↑Up 14.5% over two weeks and 6.9% jump on Aug 3 reflects strong momentum
↓Negative earnings yield and weak profitability suggest ongoing cash burn

Full analysis →

Buying

7

institutions

Selling

3

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.58 M	19.01 M	+224.54 K	-36.1%	0.00%
MM Millennium Management LLC Q2 2026	BUY	763.96 K	5.62 M	+244.60 K	-14.2%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	699.54 K	5.15 M	+620.04 K	+413.2%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	496.46 K	3.83 M	+481.61 K	+2090.4%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	394.32 K	2.90 M	+179.31 K	+7.0%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	191.00 K	1.41 M	+-11.08 K	-44.9%	0.00%
WP Woodline Partners LP Q2 2026	SELL	145.60 K	1.07 M	+-286.35 K	-80.3%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUY	33.97 K	250.01 K	+7.62 K	-24.8%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	28.50 K	209.76 K	+28.50 K	+0.0%	0.00%
AC Adar1 Capital Management, LLC Q2 2026	SELL	15.50 K	114.08 K	+-15.00 K	-70.4%	0.01%